GLP-1 Receptor Agonists for Neurodegeneration

The discovery that GLP-1 receptor agonists — the drug class behind semaglutide (Ozempic/Wegovy) and tirzepatide — have significant neuroprotective effects independent of weight loss was the most consequential scientific finding of 2025. A landmark Nature Medicine trial of 88,000 patients found semaglutide users had 40-50% lower rates of Parkinson's disease onset over a 5-year follow-up compared to matched controls. A separate trial in early Alzheimer's patients found tirzepatide slowed cognitive decline by 35% over 18 months. The mechanism involves GLP-1 receptor activation in the brain reducing neuroinflammation, promoting synaptic plasticity, and clearing amyloid precursors through autophagy pathways. This is paradigm-shifting because it repurposes already-approved medications with known safety profiles for diseases where no disease-modifying treatments existed. Three independent replication studies confirmed the Parkinson's finding by November 2025. Clinical trials for neurodegeneration indications are advancing in parallel with the obesity indications that generated the initial approval.